Actively Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Led by Monash University · Updated on 2025-10-07
900
Participants Needed
3
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services. This research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial. The treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.
CONDITIONS
Official Title
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be receiving IVIg replacement at standard dose for prevention of bacterial infections due to hypogammaglobulinaemia for at least 6 consecutive months.
- Patient is not eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.
You will not qualify if you...
- Prior or planned allogeneic haematopoietic stem cell transplantation.
- Major infection (Grade 3 or higher) in preceding 3 months, and or current active infection requiring systemic antimicrobial treatment.
- Previous splenectomy.
- Known history of bronchiectasis.
- Previous participation in this domain.
- Treating team deems enrolment in the domain is not in the best interest of the patient.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Actively Recruiting
2
Austin Hospital
Melbourne, Victoria, Australia, 3004
Actively Recruiting
3
Northern Health
Melbourne, Victoria, Australia, 3004
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here